Abstract
Immunosuppressive cells have been reported to play an important role in tumor-progression mainly because of their capability to promote immune-escape, angiogenesis, and metastasis. Among them, myeloid-derived suppressor cells (MDSCs) have been recently identified as immature myeloid cells, induced by tumor-associated inflammation, able to impair both innate and adaptive immunity. While murine MDSCs are usually identified by the expression of CD11b and Gr1, human MDSCs represent a more heterogeneous population characterized by the expression of CD33 and CD11b, low or no HLA-DR, and variable CD14 and CD15. In particular, the last two may alternatively identify monocyte-like or granulocyte-like MDSC subsets with different immunosuppressive properties. Recently, a substantial increase of MDSCs has been found in peripheral blood and bone marrow (BM) of multiple myeloma (MM) patients with a role in disease progression and/or drug resistance. Pre-clinical models recapitulating the complexity of the MM-related BM microenvironment (BMM) are major tools for the study of the interactions between MM cells and cells of the BMM (including MDSCs) and for the development of new agents targeting MM-associated immune-suppressive cells. This review will focus on current strategies for human MDSCs generation and investigation of their immunosuppressive function in vitro and in vivo, taking into account the relevant relationship occurring within the MM–BMM. We will then provide trends in MDSC-associated research and suggest potential application for the treatment of MM.
Introduction
The immune system has the potential to selectively kill tumor cells avoiding normal tissue and to generate long-lasting memory, which prevents cancer onset or recurrence. However, even if some patients achieve long-lasting complete remissions, the clinical efficacy of immunotherapy is still limited. One possible explanation should be identified in the protective milieu provided by tumor-associated inflammation and tumor-infiltrating myeloid and lymphoid cells (1, 2). The critical role of inflammation in cancer development and progression has been recognized over 150 years ago by Rudolf Virchow; however, only recently, chronic inflammation has been found to induce immunosuppression and has been associated with the development of cancer and other diseases (3–5). In the inflammatory response, myeloid effectors are the first cells attracted and recruited in the site of injury (6). Indeed, in cancer, these cells are represented by neutrophils, macrophages, dendritic cells (DCs), and the highly immunosuppressive myeloid-derived suppressor cells (MDSCs) (7). MDSCs are a heterogeneous population of immature myeloid cells generated in the bone marrow (BM) of healthy subjects that normally differentiate in mature myeloid cells without inducing immunosuppression (7). However, in pathologic conditions such as cancer, trauma, or other diseases characterized by chronic inflammation, these cells undergo abnormal expansion, are blocked in differentiation and accumulate in different sites including BM, spleen, liver, and tumor site (8, 9), sustaining (or even worsening) preexisting tumor-driven inflammation and inducing tumor-progression, neovascularization, and immune-escape (7, 10–12).
In the last decade, several studies have focused on the role of MDSCs in the regulation of immune system in solid tumors while little is reported on the role of MDSCs in hematologic malignancies, including multiple myeloma (MM) (13). MM is an incurable disease characterized by accumulation of malignant plasma cells within the BM. The interplay between MM cells and cells of the BM microenvironment (BMM) is tough to be the cause, of two widely recognized hallmarks of MM: bone disease and general immunosuppression (14–16). Recently, it has been disclosed a major role for MDSCs in MM pathobiology. Indeed, different authors demonstrated an increase of MDSCs in both peripheral blood and BM of MM patients (9, 17, 18). Moreover, it was reported that in addition to their immunosuppressive activity, MDSCs have the potential to differentiate in functional osteoclasts thus contributing to the formation of osteolytic lesions (19, 20).
This review provides an overview on current pre-clinical approaches used to study human MDSCs in vitro and in vivo, with a particular focus on MM-associated MDSCs. We will also summarize the mechanism and the molecular pathways involved in MDSC-dependent immune-dysfunction and potential translational applications of MDCSs for the therapy of MM.
Immunophenotype of MDSCs
Myeloid-derived suppressor cells were firstly identified in tumor-bearing mice on the basis of their suppressive function. Indeed, these cells lacked any surface marker specifically expressed by myeloid mature cells such as monocytes, macrophages, or DCs (21), even if morphologically they resembled granulocytes or monocytes. Further works in mice, aimed to characterize their immunophenotype, identified MDSCs as cells positive to granulocyte receptor (Gr1) and CD11b (22). The mAb used to identify Gr1, however, is able to bind the same epitope of two different molecules belonging to the lymphocyte superfamily (Ly)-6, Ly-6C, and Ly-6G, mainly expressed on monocytes and neutrophils, respectively. This led to the identification of two sub-groups of murine MDSCs, reflecting differences in term of both morphology and immunosuppressive function: CD11b+ Ly-6C+ Ly-6G− monocytic (Mo)-MDSCs, with a monocyte-like morphology, mainly expressing the inducible form of nitric oxide synthase (iNOS); and CD11b+ Ly-6C− Ly-6G+ granulocytic (G)-MDSCs [or polymorphonuclear (PMN)-MDSCs] with a granulocyte-like morphology expressing high levels of arginase 1 (ARG1) (23, 24).
Unlike murine MDSCs, the human MDSCs are less defined, lacking a Gr1 homologous. Commonly, MDSCs are defined as CD11b+ CD33+ HLA-DRlow/− cells not expressing markers of mature myeloid or lymphoid cells. As in mice, two main subsets of MDSCs could be identified: CD15+ CD14− CD11b+ CD33+ HLA-DRlow/− G-MDSCs and CD15− CD14+ CD11b+ CD33+ HLA-DRlow/− Mo-MDSCs (7, 25, 26). Furthermore, human MDSCs are extremely heterogeneous and recently different tumors were reported to generate MDSCs identified by different phenotypes (27). New markers are currently under investigation in order to better clarify their phenotype, subsets, and function. Among them, the expression of IL-4Ra and the VEGF receptors 1 and 2, on Mo-MDSCs in particular, have been associated with immunosuppressive and angiogenetic potential, respectively (7, 22). As regard to morphology, human MDSCs resemble granulocytes or monocytes at different maturation stages (28) and in cancer patients their number have been reported to directly correlate with neutrophil count (29). Taking into account the prognostic and predictive role played by neutrophil count and chronic inflammation in different malignancies (30–33), the key role of these cells in cancer patients is an emerging issue.
In MM, few reports (9, 17, 18) identified MDSCs as CD11b+ CD33+ HLA-DRlow/− cells in both peripheral blood and BM. G-MDSC resulted to be the most up-regulated and immunosuppressive subpopulation, while contrasting results were observed regarding the Mo-MDSCs. This should be due to differences in phenotypic profile, which identifies Mo-MDSCs. Indeed, while most of authors recognized G-MDSCs as CD15+ CD14− CD11b+ CD33+ HLA-DRlow/− cells, Mo-MDSCs have been alternatively identified as CD14+ CD11b+ HLA-DRlow/− (9, 18) or CD14+ CD11b+ CD33+ HLA-DRlow/− (17) or CD15− CD14− CD11b+ CD33+ cells (9). Of note, in a previous report (34), Mo-MDSCs identified as CD14+ HLA-DRlow/− cells were found to be significantly higher in patients with MM as compared to healthy subjects.
On these bases, due to the lack of a unique surface markers signature for the identification of MDSCs, functional suppressive assays remain essential.
MDSCs Function and Role in Tumor-Progression
Myeloid-derived suppressor cells inhibit the anti-tumor immune response by multiple mechanisms, probably mostly triggered by direct cell-to-cell contact and involving cell surface receptors and short-lived mediators (Figure 1). Among others, the metabolism of L-arginine was the first identified mechanism for MDSCs immunosuppression (35, 36). Specifically, L-arginine serves as a substrate for iNOs (generating NO and citrulline) and ARG1 (producing urea and ornithine). The up-regulation of both enzymes in MDSCs lead to a shortage of the non-essential amino acid in tumor microenvironment, and consequently to the impairment of T cell function. Indeed, T lymphocytes depend on arginine for proliferation, CD3ζ expression, and development of memory (37, 38). Furthermore, the increased NO production leads to suppression of T cell function through the inhibition of IL-2 downstream pathway (39, 40). An additional and related finding is that, MDSCs could also mediate the depletion of cystine and cysteine from tumor microenvironment, thus further limiting antigen-driven T cell activation (41).
Figure 1
A further hallmark of MDSC-dependent immunosuppression relies on the production of reactive oxygen species (ROS). Indeed, different studies report MDSCs from both tumor-bearing mice and cancer patients to produce a huge amount of ROS (23, 42, 43) that, in turn, reduce CD3ζ expression and antigen specific T cell proliferation (44). ROS production by MDSC is sustained by the inflammatory tumor microenvironment, enriched, among others, in IL-10, IL-6, and TGF-beta, as well as by the cell-to-cell contact with lymphocytes (37, 44).
The contemporary presence of NO and superoxide in tumor microenvironment may lead to the production of peroxynitrite, which in turn induces the nitration of different amino acids such as tyrosine, tryptophan, cysteine, and methionine (45). Nitration of T cell receptor (TCR) and CD8 molecules results in a physical modification of the receptor that alters the binding to MHC, thus impairing the capability of T cells to respond to antigen specific stimuli (46).
Recently, some authors (47) reported a new mechanism by which MDSCs inhibit the immune response against cancer. They found that MDSCs are able to down-regulate L-selectine (CD62L) levels on naïve T cells through their membrane expression of ADAM17. This event, in turn, decreases the capability of T cells to migrate to the tumor site where they would be activated.
A further mechanism of immune regulation by MDSCs relies on their capability to induce regulatory T cells (T-regs). Indeed, different studies report that MDSCs promote the clonal expansion of antigen specific natural T-regs and induce the conversion of naïve T helper cells into inducible T-regs, through a mechanism dependent on CD40-CD40L interaction; on the secretion of cytokines such as IFN-gamma, IL-10, and TGF-beta; and on the overexpression of ARG1 (37, 48–50).
More recently, MDSCs have been reported to promote Th17 differentiation and IL-17A production (51). Th17 development was shown to be dependent on IL-1b/IL-6/IL-23 and NO production by MDSCs in both tumor-bearing mice and cancer patients (52–54). To better understand the paradoxical induction of “pro-inflammatory” Th17 by “immunosuppressive” MDSCs, it should be noted that Th17 cells play a role in both tumor-progression and induction of immunosuppression. Indeed, these cells promote chronic inflammation, DNA damage, and tumor-associated angiogenesis, and on the other hand promote the local recruitment of other inflammatory cells (including MDSCs) and inhibit immune response (51, 55, 56).
A further immunosuppressive mechanism relies on the cross-talk between MDSCs and tumor-associated macrophages (TAMs) (57, 58). This strict interplay leads to a microenvironment enrichment in immune-regulatory cytokines such as IL-10, IL-6, IL-1b, VEGF, and to an immunosuppressive M2 polarization of macrophages. These cells also promote tumor-progression through different non-immune mechanism and in MM, in particular, are reported to induce cancer cell proliferation, drug resistance, and angiogenesis (59, 60).
Finally, emerging evidence suggests that MDSCs may promote immune-escape also by suppressing NK activity, overexpressing programmed death ligands (PD-L1 and PD-L2) and releasing IL-10 and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment (37, 61, 62).
Molecular Regulators of MDSCs Development and Function
The tumor-associated microenvironment produces several factors involved in myelopoiesis and impairs the myeloid differentiation. Among them, granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, M-CSF, stem cell factor, VEGF, and IL-3 are the most recognized molecules involved in MDSC generation (27, 63). Furthermore, a huge amount of cytokines and chemokines released by tumor cells or tumor-surrounding cells including IL-1β, IL-4, IL-6, IL-10, IFN-gamma, TGF-beta, CCL2, CCL5, S100A8, and S100A9, are reported to reprogram immature myeloid cells to became immunosuppressive MDSCs and to attract them in the tumor microenvironment (7, 64, 65). All these soluble mediators regulate MDSC function through the activation of different downstream signaling pathways, such as Jak/Stat, NF-κB, cyclooxygenase 2 (COX-2), and PGE2 (27, 66). Furthermore, recent evidence supports the hypothesis that a major role in this regulatory network is played by non-coding RNAs including micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs) (67–69).
STAT family
The signal transducer and activator of transcription (Stat) 3 plays, among other Stat family members, a major role in modulating MDSC function. In myeloid cells, Stat3 promotes the expression of different anti-apoptotic and pro-proliferative factors, such as Bcl-xL, c-myc, cyclin D1 and survivin, and prevent myeloid cells differentiation and maturation (66, 70). Stat3 induces the up-regulation of the calcium-binding pro-inflammatory proteins S100A9 and S100A8. Some authors reported that Stat3-dependent S100A9 up-regulation enhances MDSC generation in vitro and that the immune system of mice lacking S100A9 have a greater ability to reject the tumor implant (71). The mechanism is still not fully understood, however, it is thought that the heterodimer S100A8/S100A9 is involved in ROS generation through NAPDH oxidase (Nox2) complex and that ROS, in turn, impairs myeloid cells differentiation (71). Moreover, STAT3 up-regulates two components of the Nox2 complex, p47phox, and gp91phox, thus directly contributing to the increase in ROS production by MDSCs (72). Stat3 is also reported to interact with C/EBPβ, a transcription factor involved in myelopoiesis and control of differentiation and proliferation of myeloid progenitors. The latter could be explained, at least in part, by the capability of activated Stat3 to induce c-myc expression due to the increased binding of C/EBPβ to Myc promoter (65, 73).
Among the other members of the Stat family, Stat1 and Stat6 play a key role in MDSC activation and immunosuppressive function. Stat1 is activated by both IFN-γ and IL-1β and is involved in the expression of ARG1 and iNOS. Indeed, MDSCs from mice knock-down for STAT1 are unable to inhibit T lymphocyte activation due to a lack in up-regulation of iNOS or ARG1 (74).
IL-4 or IL-13 binding to the CD124 leads to the activation of Stat6, which, in turn, induces the expression of arginase and the production of TGFβ by MDSCs, thus contributing to the instauration of an immune-permissive microenvironment (75–77).
NF-κB
The NF-κB activity has been reported to be critical for the immunosuppressive capability of MDSCs. Toll-like receptors (TLR) via myeloid differentiation primary response gene (MyD) 88 and IL-1β are fundamental activators of NF-κB signaling and lead to the production and secretion of Th2 cytokines, IL-10, and ARG1 (66). Recently, it has been demonstrated (78) a Stat3-dependent activation of the non-canonical NF-κB pathway that, in turn, induces the transcription of IDO in MDSCs, thus elucidating a new mechanism for T cell immunity inhibition.
PGE2 and COX-2
Prostaglandin E2 is an eicosanoid that act as both pro-inflammatory and immunosuppressive molecule. Its synthesis is COX-2 dependent and its signaling relies on the receptor E-prostanoid (EP) 4, which once activated induce ARG1 up-regulation in MDSCs (79–81). EP2-knockout mice inoculated with 4T1 mammary carcinoma presented a reduced number of infiltrating MDSCs, suggesting an important role for PGE2 in MDSC induction (66). Furthermore, others provided evidence (82) that the COX-2 inhibition, which is induced with dietary celecoxib in a mesothelioma murine model, prevents the expansion of MDSCs. Together these results highlight the crucial role played by the COX-2/PGE2 signaling in MDSCs function and differentiation.
Micro-RNAs
Micro-RNAs are small non-coding RNAs able to regulate gene expression at the post-transcriptional level (83). Due to their critical role in tumor biology (84–86) and cancer–microenvironment interaction (87–90), these molecules have gained particular attention even as possible immune modulators (91, 92). Indeed, different studies identified several miRNAs involved in the complex network that regulate MDSCs development and function (67, 68).
MiR-223 was the first miRNAs associated to MDSCs (93). It has been discovered that increased PGE2 in the tumor microenvironment leads to miR-223 down-regulation in MDSCs and subsequent up-regulation of its target myeloid enhancer factor 2 (Mef2c), which promote MDSC survival and accumulation in tumor site (93). MiR-223 is involved also in myeloid cell differentiation by targeting nuclear factor I (NFI)-A and inducing differentiation of immature myeloid cells into mature granulocytes (94).
MiR-494 has been shown to be up-regulated in MDSCs by tumor-derived factors (especially from TGF-β). This miRNA revealed to sustain MDSC survival through down-regulation of PTEN and to promote tumor invasion and metastasis by regulating metalloproteinase (MMP) expression (95).
Contrasting observations were reported for miR-17-5p and miR-20a by two different studies. Specifically, some authors reported (96) that both miRNAs target AML1, leading to a down-regulation of M-CSF receptor and, consequently, to an impairment of monocyte differentiation. On the contrary, others demonstrated (97) that the tumor microenvironment led to both miRNAs down-regulation and that, according to their capability to target Stat3, their reduction leads to the up-regulation of Stat3 itself and the activation of the Stat3-dependent immunosuppressive cascade.
Using miRNA microarray, miR-21 and miR-155 have been identified as the two most up-regulated miRNAs during the induction of MDSC differentiation from BM cells (98). This up-regulation was further confirmed in tumor-bearing mice with a mechanism dependent on the presence of TGFβ in tumor microenvironment. By targeting SHIP-1 and PTEN, respectively, these miRNAs lead to Stat3 activation and MDSC proliferation and activation. Conversely, melanoma and Lewis lung carcinoma grew faster in miR-155 knockout mice and these tumors showed an increased MDSC infiltration (99). This event appears dependent on the up-regulation of HIF-1α (a direct target of miR-155) in miR-155−/− mice that leads to the enhanced expression of different chemokines and cytokines promoting MDSC recruitment, immunosuppression, and neovascularization. These apparent conflicting results may be dependent on the great heterogeneity of MDSCs and on the capability of different tumors to induce predominantly one rather than another MDSC subset. Further studies will better elucidate the role of miRNAs in MDSC-mediated cancer-associated immunosuppression.
In vitro and In vivo Approaches for Human MDSCs Study in Multiple Myeloma
It is becoming clear that the long-term success of cancer immunotherapy depends on the reprograming of the tumor-associated immune-permissive microenvironment. The great immunosuppressive potential of MDSC coupled with their capability to accumulate in tumor tissue, makes them attractive targets for the development of specific anticancer therapy. However, this relevant challenge requires the development of a stable model for the study of human MDSC response to different experimental conditions. In vitro, generation of murine MDSCs is a relatively easy process that uses embryonic, splenic, or BM myeloid progenitor cultured in a medium enriched with a combination of growth factor such as GM-CSF + G-CSF, GM-CSF + IL-6, or IL-13 (100, 101). However, this model is hampered by the interspecies differences in both surface marker and biology of immune cells (102); additionally, the possibilities to reproduce this model with human cells are low due to the poor availability of myeloid progenitors from healthy donors.
Recently, to overcome these issues, some authors developed a method to generate MDSCs from healthy donors’ peripheral blood mononuclear cells (PBMCs) (103, 104). As a first step of development of their model, authors evaluated the capability of 100 tumor cell lines to induce MDSC generation from healthy donor PBMCs during a 7-day co-culture. MDSCs so generated were phenotypically characterized and the CD33+ CD11+ HLA-DR−/low population was sorted and assayed for the capability to suppress autologous T cell proliferation in response to stimuli (104). A cytokine study was simultaneously performed to identify the main factors responsible for MDSCs’ generation (103). The authors observed that a 7-day culture with the combination GM-CSF + IL-6 was sufficient to generate a potent immunosuppressive CD33+ MDSC population. Of note, MDSCs were also generated, even if to a lesser extent, by combining GM-CSF with cytokines such as IL-1β, VEGF, TNFα, and PGE2, providing thus evidence that the presence of an inflammatory microenvironment is mandatory for MDSC generation. Furthermore, cytokine-induced MDSCs, as their tumor-induced counterpart, cause immunosuppression through the up-regulation of ARG1, iNOS, VEGF, and TGFβ (103).
In subsequent years, this model has been used to demonstrate the capability of different MM cell lines to induce, in vitro, the generation of functional MDSCs from healthy donor PBMCs and from BM aspirates (18).
Unlike in vitro studies, all models currently available for in vivo study of MDSCs are murine models. Furthermore, only two different mouse models have been used to investigate the role of MDSCs in MM. One of them is the syngeneic 5TMM mouse model inoculated with either the 5T2MM or the 5T33MM cell lines (105). These cells home in the BM and recapitulate very closely the human disease (including BM–MM cells interactions and osteolytic lesions) (105). This was the first demonstration of MDSC presence and activity in MM.
The second model was obtained inoculating mice with syngeneic murine BCM, DP 42, and ATLN MM cell lines (9). Cells in this model home to BM, and allow investigation of MDSCs in the BM milieu. By using these models, the authors discovered that MDSC infiltration of BM occurs early after tumor inoculation while, in the subsequent weeks, the percentage of infiltrating MDSC slowly decreases due to the increase of malignant PCs. Furthermore, by using S100A9 knockout transgenic mice, which have an impaired MDSC response to cancer, it has been observed a significant delay in tumor growth, which was reverted by adoptive administration of MDSCs, thus evidencing the key role played by MDSCs in tumor escape from immune system. However, the lack of models that recapitulate the complex human MM milieu limits the study of human MDSC interaction with MM cells and other component of BM milieu, thus limiting, in a translational view, the study of agents that may target specifically human MM-associated BM cells (106).
The SCID-hu model has been realized in an attempt to overcome these limitations (107–110). In this model, a human fetal bone chip is implanted in SCID mice and subsequently, primary patient malignant cells or BMSC-dependent human plasma cell line INA-6 are injected directly into the human bone implant. This model demonstrated to be suitable and reliable system to evaluate the anti-tumor activity of different drugs including different anti-inflammatory agents (108–116). This model appears to be a good candidate for the study of MDSCs, even if some immunological pitfalls should be taken into account: the allogeneic nature of BM cells respect to both primary cells or MM cell lines and the bone chips heterogeneity due to different gestational age at which they are collected (106). Both these caveats have been overcome by the use of the SCID-synth-hu model (117). This model is based on the implantation of a tridimensional bone-like polymeric scaffold into a SCID mouse and on the subsequent injection of the whole unselected cell population from BM aspirates into the implanted scaffold. This model has been successful used for pre-clinical evaluation of a variety of investigational agents (83–85, 106, 117). The recapitulation of an autologous BMM potentially offers the best model to investigate the MM-associated immunosuppressive niche and the strict interplay between MM cells and immature myeloid progenitors, including MDSCs, thus representing a unique tool for the development and evaluation of immune-modulating agents in MM.
Translational Opportunities in MM
Recently, MDSCs have been associated with immune-dysfunction in MM patients. Few reports (9, 17, 18) demonstrated the great complexity of the microenvironment in which pro-inflammatory factors co-exist with immune-suppressive mediators, in a finely tuned balance that influences patients’ outcome (118–120). Additionally, different pro-inflammatory cytokines including IL-1β, IL-6, IL-17, TNFα, and IL-23 as well as anti-inflammatory cytokines such as IL-10, TGFβ, or VEGF have been reported to be up-regulated in MM patients in both peripheral blood and BM (1, 121–123). This peculiar BMM, on one hand potently impairs the capability of resident myeloid progenitors to differentiate into DCs, macrophages, or granulocytes, and on the other reprograms mature myeloid cells to assume an immune-permissive phenotype (tolerogenic DCs, M2, N2) (7). Obviously, these events lead to a vicious circle in which MM cells drive inflammation and immunosuppression while both sustain and promote tumor growth (2, 124). To interrupt this sequence of events, different drugs are under investigation or already available in MM and other malignancies that may potentially interfere with MDSC activity and different steps (Table 1).
Table 1
| Differentiation and expansion | Intracellular modulators | Function | Depletion |
|---|---|---|---|
| ATRA | IL-6R blockers | ARG1 and iNOS inhibitors | Chemotherapeutic agents |
| HDAC inhibitors | JAK inhibitors | PDE-5 inhibitors (tadalafil, sildenafil) | Capecitabine |
| Blocking cytokines | STAT3 inhibitors | COX-2 inhibitors | Gemcitabine |
| IL-1β (anakinra) | miRNAs | Celecoxib | Doxorubicin |
| IL-6 | ROS inhibitors | IL-4Rα aptamer | |
| VEGF (bevacizumab) | Nitroaspirin | Peptibodies | |
| Blocking hematopoietic growth factor | N-Acetyl cysteine | ||
| G-CSF | Bisphosphonates | ||
| M-CSF | Zoledronate | ||
| GM-CSF |
Pre-clinical and clinical agents targeting MDSCs.
Histone-deacetylase inhibitors are a novel class of drugs involved in the epigenetic modulation of gene expression, which revealed to have great anti-tumor activity in MM (125, 126). Additionally, these agents revealed different anti-inflammatory properties related to their capability to impair, among others, the IL-6/Jak/Stat and the NF-κB signaling (127). Some authors recently reported that the histone-deacetylase inhibitor (HDAC-i) valproic acid reduces the capability of M-MDSC to transdifferentiate into G-MDSC in cancer microenvironment and induces their differentiation into macrophages or DCs, thus demonstrating a novel opportunity for the selective targeting of these immunosuppressive cells (128). Along the same line, different authors (129, 130) reported on the capability of all-trans retinoic acid (ATRA), a natural metabolite of vitamin A, to promote MDSCs differentiation into mature myeloid cells with a mechanism dependent on ERK activation and ROS reduction. This effect was also reported in cancer patients, where ATRA administration in combination with a DC based improved the immune response to vaccination by reducing the level of MDSCs in peripheral blood (131).
Blocking the cytokines involved in the immunosuppressive microenvironment may contribute to the impairment of MDSCs activity and led to benefit for cancer patients. Treatment with the IL-1β inhibitors anakinra induced serum IL-6 decrease together with a substantial increase of PFS in high-risk smoldering or indolent MM patients (132).
Myeloid-derived suppressor cells are associated with high levels of circulating VEGF (133), however, treatment with anti-VEGF drugs such as bevacizumab did not demonstrate to affect MDSC levels in peripheral blood while increased the levels of mature DCs (134, 135). Furthermore, it is conceivable that the presence of MDSCs may represent a resistance factors to the activity of this class of drugs (30, 136, 137).
As previously described, MDSC survival and differentiation is strictly dependent on STAT3 activation, thus targeting the IL-6/Jak/Stat pathway could represent an effective strategy to block them (2). Furthermore, this pathway has a clear relevance in MM pathobiology (111, 138) and the possibility to target at the same time both MM cells and their associated immunosuppressive cells is very attractive. Different agents, including monoclonal antibodies against IL-6 or IL-6 receptor, Jak inhibitors, and STAT3 inhibitors are presently under investigation (139), and other innovative approaches, such as miRNA therapy (88), are coming out from pre-clinical research.
A different approach aims to stimulate MDSC differentiation into mature cells and to limit their expansion. As shown before G/M/GM-CSF are among the most important soluble factors involved in both processes. Different authors reported a decrease of MDSCs in vivo after inhibition of these molecules, associated with a relevant tumor shrinkage (140–142). However, G- and GM-CSF are widely used in different anti-cancer treatments and in MM patients: G-CSF is used to mobilize hematopoietic stem cells, while GM-CSF is often used to improve the efficacy of cancer vaccines (143, 144). Indeed, some authors reported (17) a significant increase in MDSC number in peripheral blood stem cells after G-CSF administration and hypothesized a detrimental effect on patients undergoing transplant. GM-CSF, instead, seems to be active both as an immune-adjuvant and as a MDSC inducer in a dose-dependent manner (145, 146). In our hands, however, GM-CSF resulted to be mandatory for an efficient anti-tumor response both in vitro and cancer patients (31, 147, 148), while the patient prognosis seemed to be related to systemic inflammation at baseline. Indeed, we hypothesized that GM-CSF administration could be detrimental in patients with a high neutrophil or monocyte count (and indirectly to MDSCs) at baseline, an event that could be related to the presence of a tumor (or its associated microenvironment) able to produce this kind of cytokines by itself and from which it depends for survival and progression. Further studies are still awaited to better clarify this apparent dualistic role of hematopoietic growth factors.
As a further attempt to reduce the immunosuppressive function of MDSCs different authors tried to down-regulate the expression of COX-2, ARG1, and iNOS and to reduce ROS formation. Celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), has been reported to improve the efficacy of a DC-based immunotherapy and to reduce the tumor infiltration by MDSCs (82).
After demonstrating the capability of the phosphodiesterase-5 (PDE-5) tadalafil, to down-regulate in vitro and in vivo MDSC-dependent iNOS and Arg-1 (36), the same authors recently reported a case-report of a lenalidomide-resistant MM patients who achieved a reduction in MDSCs, and a 18-month lasting response with evident clinical benefits (149).
Bisphosphonates, such as zoledronic acid (ZOL), have been demonstrated to exert several effects and still represent interesting drugs in terms of anti-tumor and immune-stimulatory activity (150–157). Indeed, these agents revealed to impairs MDSCs at different levels and some authors (20) observed a decrease in the expansion of MM-induced MDSCs and a reduced capability to form osteoclasts after zoledronate treatment in mice. The mechanism responsible for this activity is thought to be dependent on the capability of zoledronate to decrease the activity of MMP9, thus reducing the bioavailability of VEGF and impairing the c-kit intracellular signaling (158–160).
A further strategy to improve cancer-associated immunosuppression consists in the selective depletion of MDSCs. Beyond the already known immunomodulatory capability of chemotherapeutic agents capecitabine and gemcitabine (124), and the recently discovered potential of doxorubicin, a drug that still play an important role in MM treatment, in selectively reducing MDSCs (161), some authors developed an RNA aptamer (162) able to block both murine or human IL-4 receptor α (IL-4Rα), critical for MDSC suppression function. The binding of the aptamer to its specific receptor led to MDSC depletion and tumor arrest of growth in vivo. Furthermore, others (163) recently developed an innovative method to selectively target MDSCs. By using a competitive peptide phage platform they identified peptides enriched in both M- and G-MDSCs. Subsequently, they fused the sequence of the selected peptides with the Fc portion of a murine IgG2b antibody to generate a peptibody. When used in vivo, these molecules, completely depleted circulating, intra-tumoral and intra-splenic MDSCs and induced a better tumor response compared to anti-Gr1 antibody. The main targets identified with this approach were found to be proteins bearing to the S100 family.
Finally, due to their major role in cancer-associated microenvironment (164, 165), miRNAs may represent a new frontier in the field of immunotherapeutic drugs (166). Unlike monoclonal antibodies or small inhibitor molecules already available, miRNAs have the great advantage to target pathways and network at multiple steps thus representing a powerful tool to target tumor-induced immune-dysfunction. As shown before, different miRNAs have already been reported to be involved in MDSC generation and function and other are currently under investigation (167). Several studies are presently ongoing to better define the future role of both miRNA replacement and inhibition in cancer therapy and immunotherapy making them a promise and a challenge for novel translational treatment strategies.
Concluding Remarks
During the last decade, a growing effort has been devoted to understanding the role of MM-driven immunosuppression in reducing or preventing the efficacy of immunotherapy. Among others, MDSCs revealed to play a critical role in the generation of such immune dysfunctional microenvironment in different animal models and cancer patients. On these bases it is possible to speculate that the identification of molecular pathways involved in MDSC function will lead to the development of new tailored agents able to disrupt the tumor–host immunosuppressive interactions, thus improving the efficacy of both humoral and cellular immunotherapy. We now predict a new era for immunotherapy in MM, which will provide breakthrough improvements in the treatment of this important still incurable disease.
Statements
Acknowledgments
This work has been supported by the Italian Association for Cancer Research (AIRC), PI: Pierfrancesco Tassone. “Special Program Molecular Clinical Oncology- 5 per mille” n. 9980, 2010/15.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
RossiMBottaCCorrealePTassonePTagliaferriP. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther (2013) 13(Suppl 1):S83–93.10.1517/14712598.2013.799130
2
DraghiciuOLJNijmanHWDaemenT. Myeloid derived suppressor cells – an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2014).10.4161/21624011.2014.954829
3
BalkwillFMantovaniA. Inflammation and cancer: back to Virchow?Lancet (2001) 357(9255):539–45.10.1016/S0140-6736(00)04046-0
4
Bronstein-SittonNCohen-DanielLVakninIEzernitchiAVLeshemBHalabiAet alSustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol (2003) 4(10):957–64.10.1038/ni975
5
BuntSKSinhaPClementsVKLeipsJOstrand-RosenbergS. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol (2006) 176(1):284–90.10.4049/jimmunol.176.1.284
6
CoussensLMWerbZ. Inflammation and cancer. Nature (2002) 420(6917):860–7.10.1038/nature01322
7
GabrilovichDIOstrand-RosenbergSBronteV. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12(4):253–68.10.1038/nri3175
8
KeskinovAAShurinMR. Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology (2014).10.1016/j.imbio.2014.07.017
9
RamachandranIRMartnerAPisklakovaACondamineTChaseTVoglTet alMyeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol (2013) 190(7):3815–23.10.4049/jimmunol.1203373
10
CentuoriSMTradMLaCasseCJAlizadehDLarmonierCBHankeNTet alMyeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 92(5):987–97.10.1189/jlb.0911465
11
MantovaniASicaAAllavenaPGarlandaCLocatiM. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 70(5):325–30.10.1016/j.humimm.2009.02.008
12
YiHGuoCYuXZuoDWangXY. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol (2012) 189(9):4295–304.10.4049/jimmunol.1200086
13
RomanoAConticelloCCavalliMVetroCLa FauciAParrinelloNLet alImmunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 2014:198539.10.1155/2014/198539
14
IshitsukaKHideshimaTNeriPValletSShiraishiNOkawaYet alp38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol (2008) 141(5):598–606.10.1111/j.1365-2141.2008.07044.x
15
NeriPKumarSFulcinitiMTValletSChhetriSMukherjeeSet alNeutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res (2007) 13(19):5903–9.10.1158/1078-0432.CCR-07-0753
16
TaiYTFulcinitiMHideshimaTSongWLeibaMLiXFet alTargeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 110(5):1656–63.10.1182/blood-2007-03-081240
17
FavaloroJLiyadipitiyaTBrownRYangSSuenHWoodlandNet alMyeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma (2014):1–8.10.3109/10428194.2014.904511
18
GorgunGTWhitehillGAndersonJLHideshimaTMaguireCLaubachJet alTumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood (2013) 121(15):2975–87.10.1182/blood-2012-08-448548
19
SawantADeshaneJJulesJLeeCMHarrisBAFengXet alMyeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res (2013) 73(2):672–82.10.1158/0008-5472.CAN-12-2202
20
ZhuangJZhangJLwinSTEdwardsJREdwardsCMMundyGRet alOsteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One (2012) 7(11):e48871.10.1371/journal.pone.0048871
21
BennettJARaoVSMitchellMS. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A (1978) 75(10):5142–4.10.1073/pnas.75.10.5142
22
TalmadgeJEGabrilovichDI. History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 13(10):739–52.10.1038/nrc3581
23
YounJINagarajSCollazoMGabrilovichDI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 181(8):5791–802.10.4049/jimmunol.181.8.5791
24
PeranzoniEZilioSMarigoIDolcettiLZanovelloPMandruzzatoSet alMyeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 22(2):238–44.10.1016/j.coi.2010.01.021
25
WangYGuXXiangJChenZ. Myeloid-derived suppressor cells participate in preventing graft rejection. Clin Dev Immunol (2012) 2012:731486.10.1155/2012/731486
26
ZhangBWangZWuLZhangMLiWDingJet alCirculating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 8(2):e57114.10.1371/journal.pone.0057114
27
TrikhaPCarsonWEIII. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta (2014) 1846(1):55–65.10.1016/j.bbcan.2014.04.003
28
BrandauSTrellakisSBruderekKSchmaltzDStellerGElianMet alMyeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol (2011) 89(2):311–7.10.1189/jlb.0310162
29
OhkiSShibataMGondaKMachidaTShimuraTNakamuraIet alCirculating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep (2012) 28(2):453–8.10.3892/or.2012.1812
30
BottaCBarbieriVCilibertoDRossiARoccoDAddeoRet alSystemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 14(6):469–75.10.4161/cbt.24425
31
CorrealePBottaCRotundoMSGuglielmoAConcaRLicchettaAet alGemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. J Immunother (2014) 37(1):26–35.10.1097/CJI.0000000000000004
32
KelkitliEAtayHCilingirFGulerNTerziYOzatliDet alPredicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol (2014) 93(5):841–6.10.1007/s00277-013-1978-8
33
TempletonAJPezaroCOmlinAMcNamaraMGLeibowitz-AmitRVera-BadilloFEet alSimple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 120:(21):3346–52.10.1002/cncr.28890
34
BrimnesMKVangstedAJKnudsenLMGimsingPGangAOJohnsenHEet alIncreased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol (2010) 72(6):540–7.10.1111/j.1365-3083.2010.02463.x
35
RodriguezPCQuicenoDGZabaletaJOrtizBZeaAHPiazueloMBet alArginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64(16):5839–49.10.1158/0008-5472.CAN-04-0465
36
SerafiniPMeckelKKelsoMNoonanKCalifanoJKochWet alPhosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 203(12):2691–702.10.1084/jem.20061104
37
NagarajSGabrilovichDI. Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 22(4):282–8.10.1016/j.semcancer.2012.01.010
38
RodriguezPCOchoaAC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 222:180–91.10.1111/j.1600-065X.2008.00608.x
39
BingisserRMTilbrookPAHoltPGKeesUR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol (1998) 160(12):5729–34.
40
MazzoniABronteVVisintinASpitzerJHApolloniESerafiniPet alMyeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 168(2):689–95.10.4049/jimmunol.168.2.689
41
SrivastavaMKSinhaPClementsVKRodriguezPOstrand-RosenbergS. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2010) 70(1):68–77.10.1158/0008-5472.CAN-09-2587
42
SchmielauJFinnOJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 61(12):4756–60.
43
MantovaniGMaccioAMadedduCMuraLGramignanoGLussoMRet alAntioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (2003) 81(10):664–73.10.1007/s00109-003-0476-1
44
KusmartsevSNefedovaYYoderDGabrilovichDI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 172(2):989–99.10.4049/jimmunol.172.2.989
45
LuTRamakrishnanRAltiokSYounJIChengPCelisEet alTumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 121(10):4015–29.10.1172/JCI45862
46
NagarajSSchrumAGChoHICelisEGabrilovichDI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 184(6):3106–16.10.4049/jimmunol.0902661
47
HansonEMClementsVKSinhaPIlkovitchDOstrand-RosenbergS. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 183(2):937–44.10.4049/jimmunol.0804253
48
PanPYMaGWeberKJOzao-ChoyJWangGYinBet alImmune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2010) 70(1):99–108.10.1158/0008-5472.CAN-09-1882
49
HuangBPanPYLiQSatoAILevyDEBrombergJet alGr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 66(2):1123–31.10.1158/0008-5472.CAN-05-1299
50
SerafiniPMgebroffSNoonanKBorrelloI. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 68(13):5439–49.10.1158/0008-5472.CAN-07-6621
51
ManjiliMHWangXYAbramsS. Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs. Front Immunol (2014) 5:303.10.3389/fimmu.2014.00303
52
ObermajerNWongJLEdwardsRPChenKScottMKhaderSet alInduction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med (2013) 210(7):1433–45.10.1084/jem.20121277
53
JiaoZJGaoJJHuaSHChenDYWangWHWangHet alCorrelation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol (2012) 18(38):5454–61.10.3748/wjg.v18.i38.5454
54
YazawaTShibataMGondaKMachidaTSuzukiSKenjoAet alIncreased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol (2013) 1(4):675–9.10.3892/mco.2013.134
55
CorrealePRotundoMSBottaCDel VecchioMTGinanneschiCLicchettaAet alTumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res (2012) 18(3):850–7.10.1158/1078-0432.CCR-10-3186
56
CorrealePRotundoMSBottaCDel VecchioMTTassonePTagliaferriP. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology (2012) 1(4):531–2.10.4161/onci.19404
57
Ostrand-RosenbergSSinhaPBeuryDWClementsVK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 22(4):275–81.10.1016/j.semcancer.2012.01.011
58
BeuryDWParkerKHNyandjoMSinhaPCarterKAOstrand-RosenbergS. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol (2014).10.1189/jlb.3A0414-210R
59
KimJDenuRADollarBAEscalanteLEKuetherJPCallanderNSet alMacrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 158(3):336–46.10.1111/j.1365-2141.2012.09154.x
60
BerardiSRiaRRealeADe LuisiACatacchioIMoschettaMet alMultiple myeloma macrophages: pivotal players in the tumor microenvironment. J Oncol (2013) 2013:183602.10.1155/2013/183602
61
MonuNRFreyAB. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 41(6–7):595–613.10.3109/08820139.2012.673191
62
GretenTFMannsMPKorangyF. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 11(7):802–7.10.1016/j.intimp.2011.01.003
63
SicaABronteV. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 117(5):1155–66.10.1172/JCI31422
64
GallinaGDolcettiLSerafiniPDe SantoCMarigoIColomboMPet alTumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 116(10):2777–90.10.1172/JCI28828
65
MarigoIBosioESolitoSMesaCFernandezADolcettiLet alTumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 32(6):790–802.10.1016/j.immuni.2010.05.010
66
CondamineTGabrilovichDI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2011) 32(1):19–25.10.1016/j.it.2010.10.002
67
El GazzarM. microRNAs as potential regulators of myeloid-derived suppressor cell expansion. Innate Immun (2014) 20(3):227–38.10.1177/1753425913489850
68
TianJRuiKWangS. Roles of miRNAs in regulating the differentiation and maturation of myeloid-derived suppressor cells. Med Hypotheses (2014) 83(2):151–3.10.1016/j.mehy.2014.05.006
69
HewardJALindsayMA. Long non-coding RNAs in the regulation of the immune response. Trends Immunol (2014) 35(9):408–19.10.1016/j.it.2014.07.005
70
YuHPardollDJoveR. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 9(11):798–809.10.1038/nrc2734
71
ChengPCorzoCALuettekeNYuBNagarajSBuiMMet alInhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 205(10):2235–49.10.1084/jem.20080132
72
CorzoCACondamineTLuLCotterMJYounJIChengPet alHIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 207(11):2439–53.10.1084/jem.20100587
73
ZhangHNguyen-JacksonHPanopoulosADLiHSMurrayPJWatowichSS. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood (2010) 116(14):2462–71.10.1182/blood-2009-12-259630
74
KusmartsevSGabrilovichDI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 174(8):4880–91.10.4049/jimmunol.174.8.4880
75
SinhaPClementsVKOstrand-RosenbergS. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res (2005) 65(24):11743–51.10.1158/0008-5472.CAN-05-0045
76
BronteVSerafiniPDe SantoCMarigoIToselloVMazzoniAet alIL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 170(1):270–8.10.4049/jimmunol.170.1.270
77
TerabeMMatsuiSParkJMMamuraMNoben-TrauthNDonaldsonDDet alTransforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med (2003) 198(11):1741–52.10.1084/jem.20022227
78
YuJWangYYanFZhangPLiHZhaoHet alNoncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol (2014) 193(5):2574–86.10.4049/jimmunol.1400833
79
KhaledYSAmmoriBJElkordE. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol (2013) 91(8):493–502.10.1038/icb.2013.29
80
RodriguezPCHernandezCPQuicenoDDubinettSMZabaletaJOchoaJBet alArginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 202(7):931–9.10.1084/jem.20050715
81
ZhangYLiuQZhangMYuYLiuXCaoX. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol (2009) 182(6):3801–8.10.4049/jimmunol.0801548
82
VeltmanJDLambersMEvan NimwegenMHendriksRWHoogstedenHCAertsJGet alCOX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 10:464.10.1186/1471-2407-10-464
83
TagliaferriPRossiMDi MartinoMTAmodioNLeoneEGullaAet alPromises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets (2012) 12(7):838–46.10.2174/156800912802429355
84
Di MartinoMTLeoneEAmodioNForestaULionettiMPitariMRet alSynthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 18(22):6260–70.10.1158/1078-0432.CCR-12-1708
85
AmodioNLeottaMBellizziDDi MartinoMTD’AquilaPLionettiMet alDNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 3(10):1246–58.
86
LeottaMBiamonteLRaimondiLRonchettiDDi MartinoMTBottaCet alA p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol (2014) 229(12):2106–16.10.1002/jcp.24669
87
LeoneEMorelliEDi MartinoMTAmodioNForestaUGullaAet alTargeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 19(8):2096–106.10.1158/1078-0432.CCR-12-3325
88
AmodioNBellizziDLeottaMRaimondiLBiamonteLD’AquilaPet almiR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 12(23):3650–62.10.4161/cc.26585
89
RossiMPitariMRAmodioNDi MartinoMTConfortiFLeoneEet almiR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol (2013) 228(7):1506–15.10.1002/jcp.24306
90
RaimondiLAmodioNDi MartinoMTAltomareELeottaMCaraccioloDet alTargeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 5(10):3039–54.
91
RaischJDarfeuille-MichaudANguyenHT. Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol (2013) 19(20):2985–96.10.3748/wjg.v19.i20.2985
92
RebaneAAkdisCA. MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol (2013) 132(1):15–26.10.1016/j.jaci.2013.04.011
93
LiuQZhangMJiangXZhangZDaiLMinSet almiR-223 suppresses differentiation of tumor-induced CD11b(+) Gr1(+) myeloid-derived suppressor cells from bone marrow cells. Int J Cancer (2011) 129(11):2662–73.10.1002/ijc.25921
94
FaziFRosaAFaticaAGelmettiVDe MarchisMLNerviCet alA minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell (2005) 123(5):819–31.10.1016/j.cell.2005.09.023
95
LiuYLaiLChenQSongYXuSMaFet alMicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol (2012) 188(11):5500–10.10.4049/jimmunol.1103505
96
FontanaLPelosiEGrecoPRacanicchiSTestaULiuzziFet alMicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 9(7):775–87.10.1038/ncb1613
97
ZhangMLiuQMiSLiangXZhangZSuXet alBoth miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol (2011) 186(8):4716–24.10.4049/jimmunol.1002989
98
LiLZhangJDiaoWWangDWeiYZhangCYet alMicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol (2014) 192(3):1034–43.10.4049/jimmunol.1301309
99
WangJYuFJiaXIwanowyczSWangYHuangSet alMicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer (2014).10.1002/ijc.29151
100
ObermajerNKalinskiP. Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res (2012) 1(1):15.10.1186/2047-1440-1-15
101
ZhouZFrenchDLMaGEisensteinSChenYDivinoCMet alDevelopment and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 28(3):620–32.10.1002/stem.301
102
LeslieM. Biomedical research. Immunology uncaged. Science (2010) 327(5973):1573.10.1126/science.327.5973.1573
103
LechnerMGLiebertzDJEpsteinAL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol (2010) 185(4):2273–84.10.4049/jimmunol.1000901
104
LechnerMGMegielCRussellSMBinghamBArgerNWooTet alFunctional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med (2011) 9:90.10.1186/1479-5876-9-90
105
Van ValckenborghESchouppeEMovahediKDe BruyneEMenuEDe BaetselierPet alMultiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia (2012) 26(11):2424–8.10.1038/leu.2012.113
106
TassonePNeriPBurgerRDi MartinoMTLeoneEAmodioNet alMouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets (2012) 12(7):814–22.10.2174/156800912802429292
107
UrashimaMChenBPChenSPinkusGSBronsonRTDederaDAet alThe development of a model for the homing of multiple myeloma cells to human bone marrow. Blood (1997) 90(2):754–65.
108
TassonePNeriPBurgerRSavinoRShammasMCatleyLet alCombination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res (2005) 11(11):4251–8.10.1158/1078-0432.CCR-04-2611
109
TassonePNeriPKutokJLTournilhacOSantosDDHatjiharissiEet alA SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood (2005) 106(4):1341–5.10.1182/blood-2004-11-4477
110
TassonePNeriPCarrascoDRBurgerRGoldmacherVSFramRet alA clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood (2005) 106(2):713–6.10.1182/blood-2004-11-4477
111
FulcinitiMHideshimaTVermot-DesrochesCPozziSNanjappaPShenZet alA high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 15(23):7144–52.10.1158/1078-0432.CCR-09-1483
112
FulcinitiMTassonePHideshimaTValletSNanjappaPEttenbergSAet alAnti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 114(2):371–9.10.1182/blood-2008-11-191577
113
NeriPTassonePShammasMYasuiHSchipaniEBatchuRBet alBiological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia (2007) 21(12):2519–26.10.1038/sj.leu.2404912
114
TassonePGoldmacherVSNeriPGozziniAShammasMAWhitemanKRet alCytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 104(12):3688–96.10.1182/blood-2004-03-0963
115
HideshimaTNeriPTassonePYasuiHIshitsukaKRajeNet alMLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res (2006) 12(19):5887–94.10.1158/1078-0432.CCR-05-2501
116
Ditzel SantosDHoAWTournilhacOHatjiharissiELeleuXXuLet alEstablishment of BCWM.1 cell line for Waldenstrom’s macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol (2007) 35(9):1366–75.10.1016/j.exphem.2007.05.022
117
CalimeriTBattistaEConfortiFNeriPDi MartinoMTRossiMet alA unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 25(4):707–11.10.1038/leu.2010.300
118
BryantCSuenHBrownRYangSFavaloroJAkliluEet alLong-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J (2013) 3:e148.10.1038/bcj.2013.34
119
FengPYanRDaiXXieXWenHYangS. The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma. Inflammation (2014).10.1007/s10753-014-9980-4
120
BirmannBMGiovannucciELRosnerBAColditzGA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses’ health study. Cancer Prev Res (2014) 7(1):33–41.10.1158/1940-6207.CAPR-13-0224
121
PrabhalaRHPelluruDFulcinitiMPrabhalaHKNanjappaPSongWet alElevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 115(26):5385–92.10.1182/blood-2009-10-246660
122
NoonanKMarchionniLAndersonJPardollDRoodmanGDBorrelloI. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 116(18):3554–63.10.1182/blood-2010-05-283895
123
ZhengMMZhangZBemisKBelchARPilarskiLMShivelyJEet alThe systemic cytokine environment is permanently altered in multiple myeloma. PLoS One (2013) 8(3):e58504.10.1371/journal.pone.0058504
124
WesolowskiRMarkowitzJCarsonWEIII. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1:10.10.1186/2051-1426-1-10
125
NeriPTagliaferriPDi MartinoMTCalimeriTAmodioNBulottaAet alIn vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol (2008) 143(4):520–31.10.1111/j.1365-2141.2008.07387.x
126
CeaMCagnettaAGobbiMPatroneFRichardsonPGHideshimaTet alNew insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 19(4):734–44.10.2174/1381612811306040734
127
AdcockIM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol (2007) 150(7):829–31.10.1038/sj.bjp.0707166
128
YounJIKumarVCollazoMNefedovaYCondamineTChengPet alEpigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol (2013) 14(3):211–20.10.1038/ni.2526
129
NefedovaYFishmanMShermanSWangXBegAAGabrilovichDI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 67(22):11021–8.10.1158/0008-5472.CAN-07-2593
130
KusmartsevSChengFYuBNefedovaYSotomayorELushRet alAll-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 63(15):4441–9.
131
IclozanCAntoniaSChiapporiAChenDTGabrilovichD. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother (2013) 62(5):909–18.10.1007/s00262-013-1396-8
132
LustJALacyMQZeldenrustSRDispenzieriAGertzMAWitzigTEet alInduction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 84(2):114–22.10.4065/84.2.114
133
GabrilovichDINagarajS. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162–74.10.1038/nri2506
134
FrickeIMirzaNDupontJLockhartCJacksonALeeJHet alVascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 13(16):4840–8.10.1158/1078-0432.CCR-07-0409
135
RodriguezPCErnstoffMSHernandezCAtkinsMZabaletaJSierraRet alArginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 69(4):1553–60.10.1158/0008-5472.CAN-08-1921
136
ShojaeiFWuXMalikAKZhongCBaldwinMESchanzSet alTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 25(8):911–20.10.1038/nbt1323
137
DiricanAVarolUKucukzeybekYAlacaciogluAErtenCSomaliIet alTreatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?Asian Pac J Cancer Prev (2014) 15(12):4781–6.10.7314/APJCP.2014.15.12.4781
138
Catlett-FalconeRLandowskiTHOshiroMMTurksonJLevitzkiASavinoRet alConstitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10(1):105–15.10.1016/S1074-7613(00)80011-4
139
SansonePBrombergJ. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 30(9):1005–14.10.1200/JCO.2010.31.8907
140
ShojaeiFWuXQuXKowanetzMYuLTanMet alG-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 106(16):6742–7.10.1073/pnas.0902280106
141
KowanetzMWuXLeeJTanMHagenbeekTQuXet alGranulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 107(50):21248–55.10.1073/pnas.1015855107
142
WaightJDHuQMillerALiuSAbramsSI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 6(11):e27690.10.1371/journal.pone.0027690
143
BendallLJBradstockKF. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev (2014) 25(4):355–67.10.1016/j.cytogfr.2014.07.011
144
RapoportAPAquiNAStadtmauerEAVoglDTXuYYKalosMet alCombination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 20(5):1355–65.10.1158/1078-0432.CCR-13-2817
145
SevkoAUmanskyV. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2013) 4(1):3–11.10.7150/jca.5047
146
RibechiniEGreifenbergVSandwickSLutzMB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol (2010) 199(3):273–81.10.1007/s00430-010-0151-4
147
BottaCBestosoEApollinariSCusiMGPastinaPAbbruzzeseAet alImmune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother (2012) 35(5):440–7.10.1097/CJI.0b013e31825943aa
148
CorrealePBottaCCusiMGDel VecchioMTDe SantiMMGori SavelliniGet alCetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer (2012) 130(7):1577–89.10.1002/ijc.26181
149
NoonanKAGhoshNRudrarajuLBuiMBorrelloI. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res (2014) 2(8):725–31.10.1158/2326-6066.CIR-13-0213
150
Di MartinoMTArbitrioMGuzziPHLeoneEBaudiFPiroEet alA peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol (2011) 154(4):529–33.10.1111/j.1365-2141.2011.08622.x
151
MarraMSalzanoGLeonettiCTassonePScarsellaMZappavignaSet alNanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine (2011) 7(6):955–64.10.1016/j.nano.2011.03.004
152
MarraMAbbruzzeseAAddeoRDel PreteSTassonePToniniGet alCutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets (2009) 9(7):791–800.10.2174/156800909789760285
153
CaragliaMD’AlessandroAMMarraMGiubertiGVitaleGViscomiCet alThe farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene (2004) 23(41):6900–13.10.1038/sj.onc.1207814
154
TassonePTagliaferriPViscomiCPalmieriCCaragliaMD’AlessandroAet alZoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer (2003) 88(12):1971–8.10.1038/sj.bjc.6600986
155
TassonePGaleaEForcinitiSTagliaferriPVenutaS. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol (2002) 21(4):867–73.
156
TassonePForcinitiSGaleaEMorroneGTurcoMCMartinelliVet alGrowth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia (2000) 14(5):841–4.10.1038/sj.leu.2401770
157
DieliFGebbiaNPocciaFCaccamoNMontesanoCFulfaroFet alInduction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 102(6):2310–1.10.1182/blood-2003-05-1655
158
MelaniCSangalettiSBarazzettaFMWerbZColomboMP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 67(23):11438–46.10.1158/0008-5472.CAN-07-1882
159
HeissigBHattoriKDiasSFriedrichMFerrisBHackettNRet alRecruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 109(5):625–37.10.1016/S0092-8674(02)00754-7
160
PorembkaMRMitchemJBBeltBAHsiehCSLeeHMHerndonJet alPancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 61(9):1373–85.10.1007/s00262-011-1178-0
161
AlizadehDKatsanisELarmonierN. Chemotherapeutic targeting of myeloid-derived suppressor cells. Oncoimmunology (2014) 3(1):e27359.10.4161/onci.27359
162
RothFDe La FuenteACVellaJLZosoAInverardiLSerafiniP. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res (2012) 72(6):1373–83.10.1158/0008-5472.CAN-11-2772
163
QinHLermanBSakamakiIWeiGChaSCRaoSSet alGeneration of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med (2014) 20(6):676–81.10.1038/nm.3560
164
SoonPKiarisH. MicroRNAs in the tumour microenvironment: big role for small players. Endocr Relat Cancer (2013) 20(5):R257–67.10.1530/ERC-13-0119
165
LiXWuZFuXHanW. A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int (2013) 2013:762183.10.1155/2013/762183
166
HeimbergerABGilbertMRaoGWeiJ. MicroRNAs as novel immunotherapeutics. Oncoimmunology (2013) 2(8):e25124.10.4161/onci.25124
167
YuHWSzeDMChoWC. MicroRNAs involved in anti-tumour immunity. Int J Mol Sci (2013) 14(3):5587–607.10.3390/ijms14035587
Summary
Keywords
MDSC, myeloma, immunosuppression, cancer, pre-clinical models
Citation
Botta C, Gullà A, Correale P, Tagliaferri P and Tassone P (2014) Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities. Front. Oncol. 4:348. doi: 10.3389/fonc.2014.00348
Received
13 October 2014
Accepted
23 November 2014
Published
08 December 2014
Volume
4 - 2014
Edited by
Alessandra Romano, University of Catania, Italy
Reviewed by
Peiman Hematti, University of Wisconsin-Madison, USA; Qaiser Bashir, The University of Texas MD Anderson Cancer Center, USA
Copyright
© 2014 Botta, Gullà, Correale, Tagliaferri and Tassone.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pierfrancesco Tassone, Unit of Medical Oncology, Department of Experimental and Clinical Medicine, Magna Graecia University, Viale Europa, Catanzaro 88100 Italy e-mail: tassone@unicz.it
This article was submitted to Hematology Oncology, a section of the journal Frontiers in Oncology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.